A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

Triple negative breast cancer
Epithelial ovarian cancer
Non-small cell lung cancer
Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma
Small cell lung cancer
HR+/ HER2-breast cancer
Head and neck squamous cell carcinoma
Endometrial carcinoma
Urothelial carcinoma

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

Triple negative breast cancer
Epithelial ovarian cancer
Non-small cell lung cancer
Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma
Small cell lung cancer
HR+/ HER2-breast cancer
Head and neck squamous cell carcinoma
Endometrial carcinoma
Urothelial carcinoma

A Phase I-II, First-in-Human Study of SKB264 in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types:

Triple negative breast cancer
Epithelial ovarian cancer
Non-small cell lung cancer
Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma
Small cell lung cancer
HR+/ HER2-breast cancer
Head and neck squamous cell carcinoma
Endometrial carcinoma
Urothelial carcinoma

The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).

The purpose of this study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).